# OnCo record paper-gebhart-ann-oncol (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-gebhart-ann-oncol/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-gebhart-ann-oncol" ;
  schema:name "Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial"@en ;
  schema:description "Paper cited by one technology page, indexed on Europe PMC as PubMed record 26598545 and published in Annals of Oncology; the citing page links this DOI, which is how the record was matched."@en ;
  schema:url <https://onco.cc/key-papers/paper-gebhart-ann-oncol/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1093/annonc/mdv577>, <https://pubmed.ncbi.nlm.nih.gov/26598545/>, <https://europepmc.org/article/MED/26598545> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1093/annonc/mdv577> ;
  schema:datePublished "2016"^^xsd:gYear ;
  schema:author "Gebhart G, Lamberts LE, Wimana Z, et al." ;
  onco:related <https://onco.cc/technologies/her2-pet/> ;
  onco:journals <https://onco.cc/journals/annals-of-oncology/> .